Recombinant Human Tumor necrosis factor ligand superfamily member 15 (TNFSF15)

What is TNFSF15 and what are its primary biological functions?

Tumor necrosis factor ligand superfamily member 15 (TNFSF15) is a cytokine of the TNF superfamily that plays crucial roles in vascular homeostasis and inflammatory regulation. This protein primarily functions through binding to death receptor 3 (TNFRSF25), which initiates signaling cascades that promote T-cell activation, proliferation, and generation of multiple cytokines . The TNFSF15-TNFRSF25 signaling axis is essential for effective T-cell immune responses, particularly in T-cell-mediated autoimmune diseases .

Methodologically, when studying TNFSF15's basic functions, researchers should consider both membrane-bound and soluble forms of the protein, as TNFSF15 can be cleaved by TNF converting enzyme (TACE) to produce the soluble form that maintains biological activity . This distinction is important for experimental design, as the different forms may have distinct biological effects depending on the cellular context.

How does TNFSF15 interact with pattern-recognition receptors in immune responses?

TNFSF15 significantly amplifies cytokine responses initiated by multiple pattern-recognition receptors (PRRs), including NOD2 and various Toll-like receptors (TLRs). TNFSF15:DR3 interactions have been demonstrated to dramatically enhance PRR-induced cytokine production in human monocyte-derived macrophages (MDM) and monocyte-derived dendritic cells (MDDC) .

When designing experiments to study these interactions, it's important to note that knockdown of either TNFSF15 or DR3 results in reduced NOD2-induced cytokine secretion, including both pro-inflammatory and anti-inflammatory cytokines . The experimental approach typically involves:

• siRNA-mediated knockdown of TNFSF15 or DR3

• Antibody-mediated neutralization of the receptor-ligand interaction

• Stimulation with PRR ligands such as muramyl dipeptide (MDP, for NOD2)

• Measurement of cytokine production using ELISA or multiplex assays

Researchers should consider that these amplification effects extend beyond standard PRR ligands to include responses to mycobacterial components and live bacteria, particularly relevant in intestinal myeloid cells .

What expression patterns of TNFSF15 and DR3 are observed in human immune cells?

DR3 is expressed at detectable levels on human monocyte-derived macrophages (MDM), though at lower levels than on activated T cells . Surface expression of DR3 on MDM remains relatively stable following pattern-recognition receptor stimulation.

In contrast, TNFSF15 expression on the surface of MDM increases following NOD2 stimulation, with peak expression occurring 12-24 hours after treatment with MDP (typically dosed at 100 μg/mL in experimental settings) . This temporal pattern is important for experimental design when studying TNFSF15-DR3 interactions in MDM.

For accurate assessment of TNFSF15 and DR3 expression:

• Use flow cytometry with validated antibodies (confirm specificity through positive controls such as activated T cells for DR3)

• Include siRNA knockdown controls to verify antibody specificity

• Examine both surface and intracellular expression

• Consider time-course experiments to capture dynamic changes in expression following stimulation

How do genetic variants in the TNFSF15 gene region influence disease susceptibility and progression?

TNFSF15 gene variants have been associated with multiple immune-mediated diseases, including inflammatory bowel disease (IBD) and leprosy. Among the disease-associated polymorphisms, rs6478108 and rs4979462 have shown significant impacts on immune function and disease outcomes.

The rs4979462 polymorphism specifically:

• Shows increased frequency of combined genotypes (CT + TT) and T-allele among female SLE patients compared to healthy controls (OR = 2.6, 95% CI = 1.1–6.3, p = 0.027; OR = 2.7, 95% CI = 1.2–6.3, p = 0.015, respectively)

• Is significantly associated with serositis and thrombotic manifestations in SLE patients (OR = 2.8, 95% CI = 1.1–7.1, p = 0.032; OR = 2.9, 95% CI = 1.1–7.8, p = 0.023, respectively)

The rs6478108 polymorphism:

• Modulates NOD2-induced IL-1β secretion in monocyte-derived macrophages, with A risk allele carriers showing enhanced cytokine production

• Affects cytokine responses to multiple TLR stimuli alone or in combination with NOD2 activation

• Represents a gain-of-function variant, with MDM from A risk carriers showing increased TNFSF15 expression and enhanced NOD2-induced signaling

When investigating TNFSF15 genetic variants, researchers should:

• Genotype subjects using polymerase chain reaction-restriction fragment length polymorphism and verify through direct sequencing

• Include appropriate age- and sex-matched controls

• Correlate genotypes with functional outcomes (cytokine production, signaling pathway activation)

• Consider the potential interaction between multiple genetic variants

What signaling mechanisms mediate TNFSF15-induced amplification of cytokine responses?

TNFSF15 amplifies PRR-induced cytokine secretion through complex signaling pathways. Critical mechanistic insights for researchers include:

• The directionality of signaling is from TNFSF15 to DR3, not vice versa. Experiments with recombinant DR3 fail to enhance MDP-induced cytokines, while soluble TNFSF15 successfully amplifies these responses .

• TNFSF15:DR3 signaling promotes activation of multiple pathways:

  • MAPK, NF-κB, and PI3K pathways following NOD2 stimulation

  • TRADD/FADD/MALT1 complexes

  • Caspase-8-dependent, but caspase-1-independent, IL-1 secretion

• The soluble form of TNFSF15 (cleaved by TACE) is sufficient for cytokine amplification in MDM .

When designing experiments to investigate these signaling mechanisms, researchers should:

• Use multiple approaches to block or enhance signaling (siRNA knockdown, pharmacological inhibitors, neutralizing antibodies)

• Examine early signaling events (within 15 minutes of stimulation) to capture initial pathway activation

• Include appropriate controls for pathway selectivity and cell viability

• Consider the temporal dynamics of membrane-bound versus soluble TNFSF15

What methodological approaches are effective for studying TNFSF15 in experimental systems?

When working with TNFSF15 in research settings, several methodological considerations optimize experimental outcomes:

For protein detection and quantification:

• Enzyme-linked immunosorbent assay (ELISA) for measuring TNFSF15 serum levels

• Flow cytometry for surface and intracellular expression analysis

• Western blotting for total protein and phosphorylation status assessment

For functional studies:

• siRNA-mediated knockdown of TNFSF15 or DR3 (verify knockdown efficiency by surface staining and/or qPCR)

• Neutralizing antibodies for blocking TNFSF15:DR3 interactions

• Recombinant soluble TNFSF15 protein supplementation (typically 1-100 ng/mL)

• Suboptimal stimulation conditions (e.g., 1 μg/mL MDP) to better observe amplification effects

For genetic analyses:

• PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) for genotyping

• Direct sequencing for verification

• Larger sample sizes (100+ subjects) for sufficient statistical power when studying polymorphisms

For downstream signaling assessment:

• Phospho-flow cytometry for single-cell signaling analysis

• Immunoblotting for pathway component activation

• Selective pathway inhibitors to dissect signaling requirements

How does TNFSF15 serum level correlate with disease activity in autoimmune conditions?

TNFSF15 serum levels represent a potential biomarker for disease activity in autoimmune conditions, particularly in systemic lupus erythematosus (SLE). Research findings indicate:

• SLE patients exhibit significantly higher median serum TNFSF15 concentrations compared to healthy controls

• TNFSF15 serum levels correlate positively with SLE disease activity (p = 0.012)

• The elevation of TNFSF15 is consistent with its role in promoting inflammatory responses through amplification of PRR-initiated cytokine production

When designing studies to investigate TNFSF15 as a biomarker:

• Use standardized ELISA protocols with appropriate quality controls

• Include age- and sex-matched healthy controls

• Correlate serum levels with validated disease activity indices

• Consider longitudinal sampling to track changes with disease progression or treatment response

• Account for potential confounding factors such as concurrent infections or medications

What are the optimal conditions for using recombinant TNFSF15 in experimental settings?

When working with recombinant human TNFSF15 in research applications, several technical considerations ensure optimal experimental outcomes:

Reconstitution and storage:

• Reconstitute lyophilized protein in sterile buffer (typically PBS or water)

• Prepare small aliquots to avoid freeze-thaw cycles

• Store at -80°C for long-term or -20°C for short-term use

• Avoid repeated freeze-thaw cycles which can reduce biological activity

Concentration range:

• For cell stimulation experiments: typically 1-100 ng/mL

• For amplifying PRR responses: 10-50 ng/mL is often effective

• Perform dose-response curves for each cell type and experimental system

Timing considerations:

• Pre-treatment (1-2 hours) with TNFSF15 before PRR stimulation can enhance responses

• Alternatively, co-stimulation with PRR ligands can be effective

• For observing amplification of early signaling events, simultaneous addition is preferred

Quality control:

• Verify protein activity using known responsive cell types (e.g., MDM)

• Include positive controls (e.g., LPS-induced cytokine production)

• Test for endotoxin contamination, particularly important when studying inflammatory responses

How can inconsistent results with TNFSF15 in different cell types be reconciled?

Variability in TNFSF15 responses across different cell types is common and may reflect biological realities rather than technical errors. To address this challenge:

• Verify DR3 expression on target cells, as receptor levels significantly influence responsiveness

• Consider the differentiation state of myeloid cells, as this affects both TNFSF15 and DR3 expression

• Account for donor variability by increasing sample size or using cells from the same donor for comparative experiments

• Examine potential co-receptor expression that might modulate TNFSF15:DR3 signaling

• Test both membrane-bound and soluble forms of TNFSF15, as their effects may differ between cell types

It's worth noting that while TNFSF15 amplifies cytokine secretion in response to multiple PRR stimuli in monocyte-derived cells, its effects on dectin ligand-induced anti-inflammatory cytokine secretion are minimal , indicating pathway selectivity that should be considered when interpreting experimental results.

What controls are essential when evaluating TNFSF15 genetic variant effects?

When studying the functional consequences of TNFSF15 genetic variants:

• Include multiple polymorphisms in the TNFSF15 region rather than focusing on a single variant

• Verify genotyping results using secondary methods (e.g., direct sequencing after PCR-RFLP)

• Include cell viability assessments to ensure observed effects aren't due to differential cell survival

• Test pathway selectivity by examining responses to various stimuli

• Control for population stratification in genetic association studies

• Consider gene-gene interactions, particularly with other immune-related risk loci

The rs6478108 polymorphism has been established as functionally significant through studies of 100+ healthy individuals, demonstrating its effect on NOD2-induced IL-1β secretion . This level of validation should be the standard when evaluating other TNFSF15 variants.

What are the promising therapeutic applications targeting the TNFSF15-DR3 pathway?

The TNFSF15:DR3 signaling axis represents a potential therapeutic target for inflammatory and autoimmune diseases. Current evidence suggests several promising approaches:

• Blocking TNFSF15:DR3 interactions could attenuate excessive inflammation in conditions like IBD, where TNFSF15 risk polymorphisms are gain-of-function variants

• Targeting TACE-mediated processing of TNFSF15 might provide a more selective approach than complete pathway blockade

• Pathway-specific inhibition of downstream signaling components (TRADD/FADD/MALT1 or caspase-8) could modulate specific outcomes while preserving others

• Monitoring TNFSF15 serum levels could serve as a biomarker for disease activity and treatment response in SLE and potentially other autoimmune conditions

Future research should focus on:

• Developing selective inhibitors of TNFSF15:DR3 interactions

• Exploring tissue-specific modulation of this pathway

• Investigating combination approaches targeting multiple inflammatory pathways

• Conducting larger longitudinal studies to validate TNFSF15 as a biomarker

How might TNFSF15 research inform our understanding of innate-adaptive immune crosstalk?

TNFSF15 occupies a unique position at the interface between innate and adaptive immunity:

• It enhances PRR-initiated innate immune responses in myeloid cells

• It promotes T-cell activation and proliferation

• It regulates cytokine networks that bridge innate and adaptive responses

This dual functionality positions TNFSF15 as an important mediator of immune crosstalk. Future research directions should explore:

• The impact of TNFSF15-amplified innate responses on subsequent adaptive immunity

• Temporal dynamics of TNFSF15 expression during evolving immune responses

• Cell-specific roles of TNFSF15 in different tissue microenvironments

• The contribution of TNFSF15 genetic variants to the balance between innate and adaptive immunity in various disease states

By understanding these relationships, researchers may develop more targeted approaches to modulate specific aspects of immunity while preserving beneficial immune functions.